Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046

PURPOSE: Metronomic chemotherapy (MCT) is an increasingly used treatment option in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced/metastatic breast cancer (MBC) after failure of endocrine-based therapies. METHODS: VinoMetro was a multicentre, open-...

Descripción completa

Detalles Bibliográficos
Autores principales: Krajnak, Slavomir, Decker, Thomas, Schollenberger, Lukas, Rosé, Christian, Ruckes, Christian, Fehm, Tanja, Thomssen, Christoph, Harbeck, Nadia, Schmidt, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484172/
https://www.ncbi.nlm.nih.gov/pubmed/33743073
http://dx.doi.org/10.1007/s00432-021-03599-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484172/
https://www.ncbi.nlm.nih.gov/pubmed/33743073
http://dx.doi.org/10.1007/s00432-021-03599-2

Ejemplares similares